Huntsville, Ala. — DIATHERIX Laboratories, Inc., today announced that it has acquired the patent to Tem-PCR, a diagnostic testing technology that allows for rapid identification of multiple infectious disease organisms. The acquisition from QIAGEN, a leading global provider of molecular sample and assay technologies, follows a multi-year agreement through which DIATHERIX licensed Tem-PCR from QIAGEN. Terms of the deal were not disclosed.

DIATHERIX operates as an independent CLIA-certified clinical laboratory providing advanced multiplex molecular diagnostic services to assist healthcare providers in the detection of infectious disease. With the patent acquisition, DIATHERIX plans to expand its business model to begin manufacturing and distributing diagnostic testing products to healthcare providers for on-site use. The goal is to speed the process of diagnosing and treating infectious diseases, thereby improving outcomes and lowering costs.

The full story on PR Newswire can be accessed here.

Diatherix logo